Author

Aliaksandr Prokharau

Observed names: A. Prokharau, Prokharau A., А. V. Prokharau

Institution: Belarusian State Medical University

Observed institution: Belarusian State Medical University

ORCID: 0000-0002-9429-0138

Observed ORCID: 0000-0002-9429-0138

OpenAlex ID: A5101893667

Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial

2018 · Kohei Shitara, Toshihiko Doi, et al. · The Lancet Oncology · 520

Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial

2017 · Won Seog Kim, Christian Buske, et al. · The Lancet Haematology · 78

Efficacy and Safety of Trifluridine/Tipiracil Treatment in Patients With Metastatic Gastric Cancer Who Had Undergone Gastrectomy

2019 · David H. Ilson, Josep Tabernero, et al. · JAMA Oncology · 23

PDF

2020 · Josep Tabernero, Maria Alsina, et al. · Gastric Cancer · 21

PDF

Pharmacokinetic and Safety of CT-P10, a Biosimilar Candidate to the Rituximab Reference Product, in Patients with Newly Diagnosed Advanced Stage Follicular Lymphoma (AFL)

2016 · Bertrand Coiffier, Juan-Manuel Sancho, et al. · Blood · 13

Long-term efficacy and safety of CT-P10 or rituximab in untreated advanced follicular lymphoma: a randomized phase 3 study

2021 · Christian Buske, Wojciech Jurczak, et al. · Blood Advances · 9

Overall survival results from a phase III trial of trifluridine/tipiracil versus placebo in patients with metastatic gastric cancer refractory to standard therapies (TAGS)

2018 · J. Tabernero, K. Shitara, et al. · Annals of Oncology · 8

Analysis of symptoms and functional HRQoL scales in TAGS, a phase III trial of trifluridine/tipiracil (FTD/TPI) in metastatic gastric cancer (mGC).

2019 · Maria Alsina, Josep Tabernero, et al. · Journal of Clinical Oncology · 5

Double-blind, randomized phase 3 study to compare efficacy and safety of the biosimilar CT-P10 to rituximab combined with CVP therapy in patients with previously untreated advanced-stage follicular lymphoma.

2017 · Won Seog Kim, Wojciech Jurczak, et al. · Journal of Clinical Oncology · 5

Long-Term Efficacy and Safety Results of CT-P10 and Reference Rituximab in Patients with Newly Diagnosed Advanced Stage Follicular Lymphoma: Phase III Updated Study Results with Median Follow-up of 40 Months

2019 · Christian Buske, Larry W Kwak, et al. · Blood · 3

A Double‐blind, Randomized Phase 3 Study to Compare Efficacy and Safety of Ct‐p10 to Rituximab in Combination With Cvp in Patients With Advanced‐stage Follicular Lymphoma

2017 · C. Buske, W. Kim, et al. · Hematological Oncology · 3

PDF

Efficacy and safety of trifluridine/tipiracil (FTD/TPI) in patients (pts) with metastatic gastric cancer (mGC) with or without prior gastrectomy: Results from a phase III study (TAGS).

2019 · David H. Ilson, Aliaksandr Prokharau, et al. · Journal of Clinical Oncology · 2

CT-P10 versus reference rituximab in combination with CVP in advanced-stage follicular lymphoma: Phase 3, double-blind, randomized trial

2017 · W.S. Kim, B. Coiffier, et al. · Annals of Oncology · 2

TAGS: A phase III, randomised, double-blind study of trifluridine/tipiracil (TAS-102) versus placebo in patients with refractory metastatic gastric cancer

2018 · H.-T. Arkenau, J. Tabernero, et al. · Annals of Oncology · 1

PDF

Efficacy and Safety of EG12014 (Biosimilar Trastuzumab) Compared to Reference Trastuzumab in HER2-Positive Early Breast Cancer: A Phase III Randomized Study

2026 · Chiun-Sheng Huang, Giorgi Dzagnidze, et al. · Advances in Therapy

PDF

Assessment of safety and tolerability of subcutaneous trastuzumab in patients with HER2-positive early breast cancer: Results of an open-label, randomized, multicenter, phase IIIB ESCAPE trial

2024 · Dilyara Kaidarova, Edvard Zhavrid, et al. · Cancer Treatment and Research Communications

Effect of the Airway Obstruction Severity on the Survival of Patients With Non-small Cell Lung Cancer After Surgical Treatment

2022 · Shapetska M., Mirilenko L., et al. · Emergency Cardiology and Cardiovascular Risks

Maintenance Metronomic Chemotherapy in Treatment of Metastatic Colorectal Cancer

2019 · О. V. Streltsova, А. V. Prokharau, et al. · Cancer and Clinical Oncology

PDF

Assessment of safety and tolerability of Herceptin subcutaneous administration in patients with HER2-positive early breast cancer: results of an open-label, randomized, multicenter, phase IIIB study

2017 · S. Talayeva, D. Kaidarova, et al. · The Breast

PDF

Works count: 19

Citation count: 693

H-index: 7

I10-index: 5